» Articles » PMID: 33928430

Characterization of in Vitro Phase I Metabolites of Methamnetamine in Human Liver Microsomes by Liquid Chromatography-quadrupole Time-of-flight Mass Spectrometry

Overview
Journal Int J Legal Med
Specialty Forensic Sciences
Date 2021 Apr 30
PMID 33928430
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

N-Methyl-1-(naphthalen-2-yl)propan-2-amine (methamnetamine, PAL-1046) is an amphetamine-based new psychoactive substance (NPS). Methamnetamine has been reported to cause excessive release of serotonin, and it is classified as an empathogen or entactogen. It is not regulated as a controlled substance in most countries, and there are no studies on its metabolism. In this study, in vitro phase I metabolism of methamnetamine in human liver microsomes (HLM) and flavin-containing monooxygenase (FMO) was investigated by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS). Eight metabolites of methamnetamine were identified and were structurally characterized achieved by a combination of accurate mass analysis and tandem mass spectrometry. The identified metabolic processes include N-demethylation, N-hydroxylation, aromatic hydroxylation, and a combination of these processes. N-Hydroxylated metabolites were confirmed based on expressed FMOs. The major metabolite was formed from methamnetamine via hydroxylation of the naphthalene ring after the in vitro phase I process. These results could help detect methamnetamine ingestion by NPS abusers.

Citing Articles

Metabolic Profile Analysis of Designer Benzodiazepine Etizolam in Zebrafish and Human Liver Microsomes.

Jie Z, Qin S, Zhang W, Wang J, Lu J, Qin G Metabolites. 2023; 13(6).

PMID: 37367857 PMC: 10301778. DOI: 10.3390/metabo13060699.


Interpol review of toxicology 2019-2022.

Cheng J, Hui J, Chan W, So M, Hong Y, Leung W Forensic Sci Int Synerg. 2023; 6:100303.

PMID: 36597440 PMC: 9799715. DOI: 10.1016/j.fsisyn.2022.100303.


Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Rendic S, Crouch R, Guengerich F Arch Toxicol. 2022; 96(8):2145-2246.

PMID: 35648190 PMC: 9159052. DOI: 10.1007/s00204-022-03304-3.

References
1.
Rothman R, Partilla J, Baumann M, Lightfoot-Siordia C, Blough B . Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters. J Pharmacol Exp Ther. 2012; 341(1):251-62. PMC: 3364510. DOI: 10.1124/jpet.111.188946. View

2.
Hasenhuetl P, Bhat S, Mayer F, Sitte H, Freissmuth M, Sandtner W . A kinetic account for amphetamine-induced monoamine release. J Gen Physiol. 2018; 150(3):431-451. PMC: 5839721. DOI: 10.1085/jgp.201711915. View

3.
Richeval C, Nachon-Phanithavong M, Di Fazio V, Wiart J, Humbert L, Samyn N . Prevalence of New Psychoactive Substances in Oral Fluid Specimens from French and Belgian Drivers: Comparison 2016/2017. J Anal Toxicol. 2018; 43(2):e9-e10. DOI: 10.1093/jat/bky101. View

4.
Krueger S, Williams D . Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005; 106(3):357-87. PMC: 1828602. DOI: 10.1016/j.pharmthera.2005.01.001. View

5.
Chen Y, Zane N, Thakker D, Wang M . Quantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny. Drug Metab Dispos. 2016; 44(7):975-83. PMC: 4931884. DOI: 10.1124/dmd.115.067538. View